Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 3
2011 5
2012 4
2013 3
2014 3
2015 6
2016 7
2017 5
2018 7
2019 1
2020 8
2021 13
2022 10
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
The impact of the Covid-19 pandemic on breast cancer early detection and screening.
Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium; Figueroa JD, Gray E, Pashayan N, Deandrea S, Karch A, Vale DB, Elder K, Procopio P, van Ravesteyn NT, Mutabi M, Canfell K, Nickson C. Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium, et al. Among authors: van ravesteyn nt. Prev Med. 2021 Oct;151:106585. doi: 10.1016/j.ypmed.2021.106585. Epub 2021 Jun 30. Prev Med. 2021. PMID: 34217412 Free PMC article.
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP, Geuzinge HA, Stout NK, Alagoz O, Hampton J, Kerlikowske K, de Koning HJ, Miglioretti DL, van Ravesteyn NT, Schechter C, Sprague BL, Tosteson ANA, Trentham-Dietz A, Weaver D, Yaffe MJ, Yeh JM, Couch FJ, Hu C, Kraft P, Polley EC, Mandelblatt JS, Kurian AW, Robson ME; Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET), in collaboration with the Breast Cancer Surveillance Consortium (BCSC), and the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Lowry KP, et al. Among authors: van ravesteyn nt. JAMA Oncol. 2022 Apr 1;8(4):587-596. doi: 10.1001/jamaoncol.2021.6204. JAMA Oncol. 2022. PMID: 35175286 Free PMC article.
Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: Follow-up results of the TRIDENT-2 study.
van Prooyen Schuurman L, Sistermans EA, Van Opstal D, Henneman L, Bekker MN, Bax CJ, Pieters MJ, Bouman K, de Munnik S, den Hollander NS, Diderich KEM, Faas BHW, Feenstra I, Go ATJI, Hoffer MJV, Joosten M, Komdeur FL, Lichtenbelt KD, Lombardi MP, Polak MG, Jehee FS, Schuring-Blom H, Stevens SJC, Srebniak MI, Suijkerbuijk RF, Tan-Sindhunata GM, van der Meij KRM, van Maarle MC, Vernimmen V, van Zelderen-Bhola SL, van Ravesteyn NT, Knapen MFCM, Macville MVE, Galjaard RH; Dutch NIPT consortium. van Prooyen Schuurman L, et al. Among authors: van ravesteyn nt. Am J Hum Genet. 2022 Jun 2;109(6):1140-1152. doi: 10.1016/j.ajhg.2022.04.018. Am J Hum Genet. 2022. PMID: 35659929 Free PMC article.
More on screening mammography.
van Ravesteyn NT, Heijnsdijk EA, de Koning HJ. van Ravesteyn NT, et al. N Engl J Med. 2011 Jan 20;364(3):282-3; author reply 285-6. doi: 10.1056/NEJMc1011881. N Engl J Med. 2011. PMID: 21247323 No abstract available.
Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: Follow-up results of the TRIDENT-2 study.
van Prooyen Schuurman L, Sistermans EA, Van Opstal D, Henneman L, Bekker MN, Bax CJ, Pieters MJ, Bouman K, de Munnik S, den Hollander NS, Diderich KEM, Faas BHW, Feenstra I, Go ATJI, Hoffer MJV, Joosten M, Komdeur FL, Lichtenbelt KD, Lombardi MP, Polak MG, Jehee FS, Schuring-Blom H, Stevens SJC, Srebniak MI, Suijkerbuijk RF, Tan-Sindhunata GM, van der Meij KRM, van Maarle MC, Vernimmen V, van Zelderen-Bhola SL, van Ravesteyn NT, Knapen MFCM, Macville MVE, Galjaard RH; Dutch NIPT consortium. van Prooyen Schuurman L, et al. Among authors: van ravesteyn nt. Am J Hum Genet. 2022 Jul 7;109(7):1344. doi: 10.1016/j.ajhg.2022.06.003. Am J Hum Genet. 2022. PMID: 35803237 Free PMC article. No abstract available.
Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts.
Trentham-Dietz A, Alagoz O, Chapman C, Huang X, Jayasekera J, van Ravesteyn NT, Lee SJ, Schechter CB, Yeh JM, Plevritis SK, Mandelblatt JS; Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET). Trentham-Dietz A, et al. Among authors: van ravesteyn nt. PLoS Comput Biol. 2021 Jun 17;17(6):e1009020. doi: 10.1371/journal.pcbi.1009020. eCollection 2021 Jun. PLoS Comput Biol. 2021. PMID: 34138842 Free PMC article. Review.
Reply to Koleva-Kolarova et al.
de Koning HJ, Alagoz O, Schechter CB, van Ravesteyn NT. de Koning HJ, et al. Among authors: van ravesteyn nt. Breast. 2016 Jun;27:182-3. doi: 10.1016/j.breast.2016.01.005. Epub 2016 Mar 2. Breast. 2016. PMID: 26946960 No abstract available.
The potential of breast cancer screening in Europe.
Zielonke N, Kregting LM, Heijnsdijk EAM, Veerus P, Heinävaara S, McKee M, de Kok IMCM, de Koning HJ, van Ravesteyn NT; EU-TOPIA collaborators. Zielonke N, et al. Among authors: van ravesteyn nt. Int J Cancer. 2021 Jan 15;148(2):406-418. doi: 10.1002/ijc.33204. Epub 2020 Jul 30. Int J Cancer. 2021. PMID: 32683673 Free PMC article.
77 results